Abstract
Protein kinase CK2 is a ubiquitous, essential, and highly pleiotropic protein kinase whose abnormally high constitutive activity is suspected to underlie its pathogenic potential in neoplasia and other diseases. A number of structurally unrelated CK2 inhibitors, tested on a variety of cells derived from tumours, including lymphomas, leukaemias, multiple myeloma and prostate carcinoma, display a proapoptotic effect which is roughly proportional to their in vitro inhibitory potency. In the present review we summarize the most recent discovery of potent and selective CK2 inhibitors and their prospective as future anticancer agents.
Keywords: Protein kinase CK2, casein kinase 2, anticancer drugs, drug discovery
Anti-Cancer Agents in Medicinal Chemistry
Title: Protein Kinase CK2 Inhibitors: Emerging Anticancer Therapeutic Agents?
Volume: 8 Issue: 7
Author(s): Andrea Bortolato, Giorgio Cozza and Stefano Moro
Affiliation:
Keywords: Protein kinase CK2, casein kinase 2, anticancer drugs, drug discovery
Abstract: Protein kinase CK2 is a ubiquitous, essential, and highly pleiotropic protein kinase whose abnormally high constitutive activity is suspected to underlie its pathogenic potential in neoplasia and other diseases. A number of structurally unrelated CK2 inhibitors, tested on a variety of cells derived from tumours, including lymphomas, leukaemias, multiple myeloma and prostate carcinoma, display a proapoptotic effect which is roughly proportional to their in vitro inhibitory potency. In the present review we summarize the most recent discovery of potent and selective CK2 inhibitors and their prospective as future anticancer agents.
Export Options
About this article
Cite this article as:
Bortolato Andrea, Cozza Giorgio and Moro Stefano, Protein Kinase CK2 Inhibitors: Emerging Anticancer Therapeutic Agents?, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (7) . https://dx.doi.org/10.2174/187152008785914761
DOI https://dx.doi.org/10.2174/187152008785914761 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [ Hot Topic: Highlights on Important Signaling Pathways as Drug Targets in Hematological Malignancies (Guest Editors: H. Serve and H.C. Hasselbalch) ]
Current Drug Targets Plant Ribonucleases and Nucleases as Antiproliferative Agens Targeting Human Tumors Growing in Mice
Recent Patents on DNA & Gene Sequences New Treatment Approaches in Acute Myeloid Leukemia: Review of Recent Clinical Studies
Reviews on Recent Clinical Trials The Shape of the Messenger: Using Protein Structure Information to Design Novel Cytokine-based Therapeutics
Current Pharmaceutical Design Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent
Current Cancer Drug Targets miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Immune Mechanism, Aging, Season and Diseases: Modulatory Role of Melatonin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Random Mutagenesis Methods for In Vitro Directed Enzyme Evolution
Current Protein & Peptide Science Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Drug-Induced Hypokalaemia
Current Drug Safety The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
Current Drug Targets Exploiting Innate γδ T Lymphocytes for Tumor Immunotherapy
Recent Patents on Biomarkers Targeted α-Particle Therapy: A Clinical Overview
Current Radiopharmaceuticals CXXC5 Associates with Smads to Mediate TNF-α Induced Apoptosis
Current Molecular Medicine Novel Therapeutic Approaches Targeting Vascular Endothelial Growth Factor and its Receptors in Haematological Malignancies
Current Cancer Drug Targets The Influence of Wuzhi Capsule on the Pharmacokinetics of Cyclophosphamide
Recent Patents on Anti-Cancer Drug Discovery Microenvironment and Brain Tumor Stem Cell Maintenance: Impact of the Niche
Anti-Cancer Agents in Medicinal Chemistry Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection
Infectious Disorders - Drug Targets Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia
Current Drug Targets